Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Genome-wide methylation maps for untreated and Aza treated AML3 cells

PROVIDER: PRJNA242396 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR1171540_1.fastq.gz	Fastqsanger.gz
	SRR1171540_2.fastq.gz	Fastqsanger.gz
	SRR1171550_1.fastq.gz	Fastqsanger.gz
	SRR1171550_2.fastq.gz	Fastqsanger.gz
	SRR1171541_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Homo sapiens

Project description:Expression data from untreated and Aza treated AML3 cells

| PRJNA242395 | ENA

Aza treated AML3 cells

Project description:Aza treated AML3 cells

| PRJNA242393 | ENA

Genome-wide methylation maps for untreated and Aza treated AML3 cells

Project description:AML3 cells were treated with Azacytidine and compared against untreated cells Examination of methylation status in human untreated and Azacytidine treated AML3 cells

2014-07-01 | E-GEOD-55124 | biostudies-arrayexpress

Homo sapiens immortalized MSCs: KP vs. 3A6

Project description:Gene methylation profiling of immortalized human mesenchymal stem cells comparing HPV E6/E7-transfected MSCs cells with human telomerase reverse transcriptase (hTERT)- and HPV E6/E7-transfected MSCs. hTERT may increase gene methylation in MSCs. Goal was to determine the effects of different transfected genes on global gene methylation in MSCs.

2011-08-25 | GSE23936 | GEO

Genome-wide methylation maps for untreated and Aza treated AML3 cells

Project description:AML3 cells were treated with Azacytidine and compared against untreated cells

2014-07-01 | GSE55124 | GEO

Expression data from untreated and Aza treated AML3 cells

Project description:AML3 cells were treated with Azacytidine and compared against untreated cells

2014-07-01 | GSE55123 | GEO

E-GEOD-55123

Project description:Expression data from untreated and Aza treated AML3 cells

2019-05-14 | E-GEOD-55123 | ExpressionAtlas

LC-MSMS of the MHC-I immunopeptidome of AML cell line, THP-1

Project description:The hypomethylating agent 5-azacytidine (AZA) is the first-line induction therapy for AML patients unsuitable for intensive chemotherapy. The anti-tumor effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic regions such as cancer-testis antigens (CTAs), or endogenous retroelements (EREs). However, clear evidence supporting higher ERE MAPs presentation after AZA treatment in AML is lacking. Interestingly, we find that AZA-mediated DNMT2 inhibition leads to autophagy induction, which is responsible for mitigating ERE MAPs generation. To validate our findings, we examined the immunopeptidome of THP-1 cells treated with AZA combined with autophagy inhibitor, Spautin-1 or decitabine (DAC, non-DNMT2 inhibiting HMA) through a proteogenomic approach.

2024-04-17 | PXD046853 | Pride

Expression data from untreated and Aza treated AML3 cells

Project description:AML3 cells were treated with Azacytidine and compared against untreated cells We used RNA-Seq to detail the global programme of gene expression in human untreated and Azacytidine treated AML3 cells

2014-07-01 | E-GEOD-55123 | biostudies-arrayexpress

Homo sapiens immortalized MSCs: KP vs. 3A6

2011-08-24 | E-GEOD-23936 | biostudies-arrayexpress